Liability of the voltage-gated sodium channel gene SCN2A R19K polymorphism to oxaliplatin-induced peripheral neuropathy.

Abstract

AIM:

It was the aim of this study to test the hypothesis that the voltage-gated sodium channel gene SCN2A R19K polymorphism confers liability to oxaliplatin-induced peripheral neuropathy (OXLIPN).

METHODS:

Sixty-two patients with advanced colorectal cancer were genotyped, using allele-specific primers and SYBR green in real-time polymerase chain reaction. All patients had received adjuvant oxalipla-tin-based chemotherapy. The severity of OXLIPN was defined by means of the clinical total neuropathy score. Following the discontinuation of treatment, 36/62 patients (58.1%) developed OXLIPN. Grade I neurotoxicity was revealed in 14 (38.9%) patients and grade II neurotoxicity in 22 (61.1%) patients.

RESULTS:

From patients without OXLIPN (n = 26), 80.8% (n = 21) were homozygous for G, 19.2% (n = 5) were heterozygous (AG) and none was homozygous for A. The corresponding percentages for patients developing any grade of OXLIPN (n = 36) were similar. Likewise, among patients experiencing OXLIPN, insignificant differences in R19K genotypes were revealed between those with grade I versus grade II neurotoxicity.

CONCLUSION:

Our study failed to provide evidence to support a causal relationship between the SCN2A R19K polymorphism and OXLIPN.

• Authors: Andreas A Argyriou, Anna G Antonacopoulou, Chrisoula D Scopa, Anastasia Kottorou, Athina Kominea, Stavros Peroukides, Haralabos P Kalofonos
• Journal: Oncology (Oncology) Vol. 77 Issue 3-4 Pg. 254-6 ( 2009) ISSN: 1423-0232 [Electronic] Switzerland
• PMID: 19738391 (Publication Type: Journal Article)
• Copyright: Copyright 2009 S. Karger AG, Basel.

Chemical References

• Antineoplastic Agents
• NAV1.2 Voltage-Gated Sodium Channel
• Nerve Tissue Proteins
• Organoplatinum Compounds
• SCN2A protein, human
• Sodium Channels
• Oxaliplatin

Topics

• Aged
• Antineoplastic Agents (adverse effects)
• Female
• Humans
• Male
• Middle Aged
• NAV1.2 Voltage-Gated Sodium Channel
• Nerve Tissue Proteins (genetics)
• Organoplatinum Compounds (adverse effects)
• Oxaliplatin
• Peripheral Nervous System Diseases (chemically induced)
• Polymorphism, Genetic
• Sodium Channels (genetics)